Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial
机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China[2]The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital), Xian, China[3]Anyang Cancer Hospital, Anyang, China[4]Beijing University Cancer Hospital & Institute, Beijing, China[5]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Beijing, China[6]Peking University Cancer Hospital and Institute, Beijing, China[7]Yantai Yuhuangding Hospital, Yantai, China[8]Ordos School of Clinical Medicine I.M.M.U, Ordos, China[9]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[10]Chifeng Affiliated Hospital, Chifeng, China[11]Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610042, China, Chengdu, China四川省肿瘤医院[12]Liaoning cancer hospital & institute, Shenyang, China[13]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Insti, Beijing, China[14]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Beijing, China[15]Peking University Cancer Hospital & Institute, Beijing, China
Beijing Health and Health Science Technology Achievements and Appropriate Technology Promotion Project [BHTPP202026]; Chinese Society of Clinical Oncology (CSCO)-Linghang cancer research [Y-2019AZMS-0519]
第一作者机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
推荐引用方式(GB/T 7714)：
Jiayi Yu,Leilei Jiang,Lina Zhao,et al.Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16_SUPPL):doi:10.1200/JCO.2023.41.16_suppl.8587.
APA：
Jiayi Yu,Leilei Jiang,Lina Zhao,Xiaomin Wang,Xue Yang...&Anhui Shi.(2023).Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial.JOURNAL OF CLINICAL ONCOLOGY,41,(16_SUPPL)
MLA：
Jiayi Yu,et al."Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial".JOURNAL OF CLINICAL ONCOLOGY 41..16_SUPPL(2023)
医学